{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:23:48Z","timestamp":1790936628189,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1124\/jpet.107.121715","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T17:39:01Z","timestamp":1179941941000},"page":"862-870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models"],"prefix":"10.1016","volume":"322","author":[{"given":"Luis R.","family":"Gardell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Pounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Veinbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnete","family":"Dyssegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Brunmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Brann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Hacksell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Bonhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.121715_bib1","doi-asserted-by":"crossref","unstructured":"Bagdy G (1996) Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH\/corticosterone responses. Behav Brain Res 73: 277\u2013280.","DOI":"10.1016\/0166-4328(96)00112-X"},{"key":"10.1124\/jpet.107.121715_bib2","doi-asserted-by":"crossref","unstructured":"Bowers BJ, Henry MB, Thielen RJ, and McBride WJ (2000) Serotonin 5-HT2 receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J Neurochem 75: 1625\u20131633.","DOI":"10.1046\/j.1471-4159.2000.0751625.x"},{"key":"10.1124\/jpet.107.121715_bib3","doi-asserted-by":"crossref","unstructured":"Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 (Suppl 1): S10\u2013S14.","DOI":"10.1055\/s-2006-931483"},{"key":"10.1124\/jpet.107.121715_bib4","doi-asserted-by":"crossref","unstructured":"Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, and Waters N (1999) The 5-HT2A receptor antagonist M100907 is more effective in counter-acting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106: 123\u2013129.","DOI":"10.1007\/s007020050144"},{"key":"10.1124\/jpet.107.121715_bib5","doi-asserted-by":"crossref","unstructured":"Clemens JA, Smalstig EB, and Sawyer BD (1974) Antipsychotic drugs stimulate prolactin release. Psychopharmacologia 40: 123\u2013127.","DOI":"10.1007\/BF00421361"},{"key":"10.1124\/jpet.107.121715_bib6","doi-asserted-by":"crossref","unstructured":"Creese I, Burt DR, and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481\u2013483.","DOI":"10.1126\/science.3854"},{"key":"10.1124\/jpet.107.121715_bib7","doi-asserted-by":"crossref","unstructured":"Cutler AJ (2003) Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28 (Suppl 1): 69\u201382.","DOI":"10.1016\/S0306-4530(02)00113-0"},{"key":"10.1124\/jpet.107.121715_bib8","doi-asserted-by":"crossref","unstructured":"De Souza EB (1986) Serotonin and dopamine receptors in the rat pituitary gland: autoradiographic identification, characterization, and localization. Endocrinology 119: 1534\u20131542.","DOI":"10.1210\/endo-119-4-1534"},{"key":"10.1124\/jpet.107.121715_bib9","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, and Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23: 8836\u20138843.","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003"},{"key":"10.1124\/jpet.107.121715_bib10","doi-asserted-by":"crossref","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, and Meltzer HY (2001) 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521\u20131531.","DOI":"10.1046\/j.1471-4159.2001.00154.x"},{"key":"10.1124\/jpet.107.121715_bib11","doi-asserted-by":"crossref","unstructured":"Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, and Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302: 1129\u20131134.","DOI":"10.1124\/jpet.102.035303"},{"key":"10.1124\/jpet.107.121715_bib12","doi-asserted-by":"crossref","unstructured":"Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, et al. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968\u2013981.","DOI":"10.1016\/S0022-3565(25)12956-X"},{"key":"10.1124\/jpet.107.121715_bib13","doi-asserted-by":"crossref","unstructured":"Kuroki T, Meltzer HY, and Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774\u2013781.","DOI":"10.1016\/S0022-3565(24)38019-X"},{"key":"10.1124\/jpet.107.121715_bib14","doi-asserted-by":"crossref","unstructured":"Kuroki T, Meltzer HY, and Ichikawa J (2003) 5-HT 2A receptor stimulation by DOI, a 5-HT 2A\/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 972: 216\u2013221.","DOI":"10.1016\/S0006-8993(03)02516-2"},{"key":"10.1124\/jpet.107.121715_bib15","doi-asserted-by":"crossref","unstructured":"Li XM, Perry KW, Wong DT, and Bymaster FP (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136: 153\u2013161.","DOI":"10.1007\/s002130050551"},{"key":"10.1124\/jpet.107.121715_bib16","doi-asserted-by":"crossref","unstructured":"Li Z, Ichikawa J, Dai J, and Meltzer HY (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493: 75\u201383.","DOI":"10.1016\/j.ejphar.2004.04.028"},{"key":"10.1124\/jpet.107.121715_bib17","doi-asserted-by":"crossref","unstructured":"Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, and Meltzer HY (2005) ACP-103, a 5-HT2A\/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 183: 144\u2013153.","DOI":"10.1007\/s00213-005-0170-9"},{"key":"10.1124\/jpet.107.121715_bib18","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209\u20131223.","DOI":"10.1056\/NEJMoa051688"},{"key":"10.1124\/jpet.107.121715_bib19","doi-asserted-by":"crossref","unstructured":"Markianos M, Hatzimanolis J, and Lykouras L (2001) Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 251: 141\u2013146.","DOI":"10.1007\/s004060170049"},{"key":"10.1124\/jpet.107.121715_bib20","doi-asserted-by":"crossref","unstructured":"Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320: 486\u2013496.","DOI":"10.1124\/jpet.106.106989"},{"key":"10.1124\/jpet.107.121715_bib21","doi-asserted-by":"crossref","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600\u2013610.","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"10.1124\/jpet.107.121715_bib22","doi-asserted-by":"crossref","unstructured":"Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263\u2013287.","DOI":"10.1093\/schbul\/17.2.263"},{"key":"10.1124\/jpet.107.121715_bib23","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Matsubara S, and Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 p Ki values. J Pharmacol Exp Ther 251: 238\u2013246.","DOI":"10.1016\/S0022-3565(25)20710-8"},{"key":"10.1124\/jpet.107.121715_bib24","doi-asserted-by":"crossref","unstructured":"Meltzer HY and McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233\u2013255.","DOI":"10.1093\/oxfordjournals.schbul.a033376"},{"key":"10.1124\/jpet.107.121715_bib25","doi-asserted-by":"crossref","unstructured":"Moghaddam B and Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755\u20131760.","DOI":"10.1111\/j.1471-4159.1990.tb01230.x"},{"key":"10.1124\/jpet.107.121715_bib26","unstructured":"National Research Council (1996) Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC."},{"key":"10.1124\/jpet.107.121715_bib27","doi-asserted-by":"crossref","unstructured":"Reavill C, Kettle A, Holland V, Riley G, and Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126: 572\u2013574.","DOI":"10.1038\/sj.bjp.0702350"},{"key":"10.1124\/jpet.107.121715_bib28","doi-asserted-by":"crossref","unstructured":"Saller CF, Czupryna MJ, and Salama AI (1990) 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253: 1162\u20131170.","DOI":"10.1016\/S0022-3565(25)13217-5"},{"key":"10.1124\/jpet.107.121715_bib29","doi-asserted-by":"crossref","unstructured":"Schmidt CJ and Fadayel GM (1996) Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 277: 1541\u20131549.","DOI":"10.1016\/S0022-3565(25)13106-6"},{"key":"10.1124\/jpet.107.121715_bib30","doi-asserted-by":"crossref","unstructured":"Snyder SH (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133: 197\u2013202.","DOI":"10.1176\/ajp.133.2.197"},{"key":"10.1124\/jpet.107.121715_bib31","doi-asserted-by":"crossref","unstructured":"Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, and Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374\u20131384.","DOI":"10.1016\/S0022-3565(25)39339-0"},{"key":"10.1124\/jpet.107.121715_bib32","unstructured":"Tallarida RJ and Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs, 2 ed. Springer-Verlag, New York."},{"key":"10.1124\/jpet.107.121715_bib33","doi-asserted-by":"crossref","unstructured":"Tallarida RJ, Stone DJ Jr, and Raffa RB (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61: PL417\u2013PL425.","DOI":"10.1016\/S0024-3205(97)01030-8"},{"key":"10.1124\/jpet.107.121715_bib34","doi-asserted-by":"crossref","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, et al. (2006) Pharmacological and behavioral profile of ACP-103, a novel 5-HT2A receptor inverse agonist. J Pharmacol Exp Ther 317: 910\u2013918.","DOI":"10.1124\/jpet.105.097006"},{"key":"10.1124\/jpet.107.121715_bib35","doi-asserted-by":"crossref","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, et al. (2001) 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299: 268\u2013276.","DOI":"10.1016\/S0022-3565(24)29327-7"},{"key":"10.1124\/jpet.107.121715_bib36","doi-asserted-by":"crossref","unstructured":"Yan QS, Reith ME, Jobe PC, and Dailey JW (1997) Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765: 149\u2013158.","DOI":"10.1016\/S0006-8993(97)00568-4"},{"key":"10.1124\/jpet.107.121715_bib37","doi-asserted-by":"crossref","unstructured":"Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, and Shen YC (2005) Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 178: 35\u201340.","DOI":"10.1007\/s00213-004-1975-7"},{"key":"10.1124\/jpet.107.121715_bib38","doi-asserted-by":"crossref","unstructured":"Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D\u2019Souza DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan K, Petersen BR, et al. (2002) Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (\u2013)DOI. J Neurosci 22: 9635\u20139642.","DOI":"10.1523\/JNEUROSCI.22-21-09635.2002"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.121715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:21:39Z","timestamp":1740003699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524340157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0022356524340157"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.121715","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.121715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}